Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; Ponesimod Phase II Study Group. Freedman MS, et al. Neurology. 2022 Aug 23;99(8):e762-e774. doi: 10.1212/WNL.0000000000200606. Epub 2022 Jun 6. Neurology. 2022. PMID: 35667837 Free PMC article. Clinical Trial.
Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O'Brien F; Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Freedman MS, et al. Mult Scler. 2005 Feb;11(1):41-5. doi: 10.1191/1352458505ms1126oa. Mult Scler. 2005. PMID: 15732265 Clinical Trial.
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. O'Connor PW, et al. Among authors: freedman ms. Neurology. 2006 Mar 28;66(6):894-900. doi: 10.1212/01.wnl.0000203121.04509.31. Neurology. 2006. PMID: 16567708 Clinical Trial.
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K; PRIVIG Study Group; UBC MS/MRI Research Group. Fazekas F, et al. Among authors: freedman ms. Neurology. 2008 Jul 22;71(4):265-71. doi: 10.1212/01.wnl.0000318281.98220.6f. Neurology. 2008. PMID: 18645164 Clinical Trial.
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, Olsson TP, Miller A, Benzerdjeb H, Li H, Simonson C, O'Connor PW; Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center. Freedman MS, et al. Neurology. 2012 Jun 5;78(23):1877-85. doi: 10.1212/WNL.0b013e318258f7d4. Epub 2012 May 23. Neurology. 2012. PMID: 22622860 Clinical Trial.
327 results